VC-backed Harpoon Therapeutics debuts IPO
South San Francisco-based Harpoon Therapeutics Inc, a clinical-stage immunotherapy company, has raised $75.6 million for its IPO after pricing its 5.4 million shares at $14 per share. The stock began trading February 8, 2019 on the NASDAQ under the ticker symbol "HARP." Citigroup and SVB Leerink are the lead underwriters. Harpoon's pre-IPO backers include OrbiMed, Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures, NS Investment, MPM Capital, Oncology Impact Fund, Arix Bioscience, New Leaf Venture Partners and Taiho Ventures LLC.
8 February 2019•2 mins read
